title: Adherence to cervical screening in the era of human papillomavirus vaccination: how low is too low?
abstract: Human papillomavirus vaccine prevents infection by two major oncogenic types of the virus. Continued screening is needed in vaccinated women to prevent cancers caused by high-risk types not included in the vaccine. An exaggerated sense of protection from the vaccine could lead to a decline in the rate of screening among vaccinated women, which in principle could lead to an increase in the incidence of cervical cancer. We present a simple mathematical model of vaccination, screening, and disease incidence, including an analysis of the effect of data uncertainties. For a population with opportunistic screening and 30% vaccine coverage, screening rates in vaccinated women would have to decline by at least 80% (median value of probabilistic uncertainty analysis) before the incidence of cervical cancer would increase in the era since the introduction of the vaccine. By comparison, the decline needed is at least 49% in a population with organised screening and 70% vaccine coverage. In populations that have highly effective cervical screening programmes, incidence of cervical cancer starts to increase after smaller, but still substantial, decreases in screening. Introduction of vaccine is unlikely to lead to an increased incidence of cervical cancer as a result of diminished screening.
authors.affiliation: Department of Mathematics and Statistics, University of Guelph, Guelph, ON, Canada. cbauch@uoguelph.ca
authors.forename: Chris T
authors.initials: CT
authors.lastname: Bauch
authors.forename: Meng
authors.initials: M
authors.lastname: Li
authors.forename: Gretchen
authors.initials: G
authors.lastname: Chapman
authors.forename: Alison P
authors.initials: AP
authors.lastname: Galvani
mesh_terms: D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008403:Mass Screening; D008962:Models, Theoretical; D030361:Papillomavirus Infections / Q000453:epidemiology / Q000517:prevention & control; D053918:Papillomavirus Vaccines / Q000627:therapeutic use*; D012307:Risk Factors; D012680:Sensitivity and Specificity; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control; D014626:Vaginal Smears; D002578:Uterine Cervical Dysplasia / Q000175:diagnosis / Q000517:prevention & control / Q000821:virology
chemical_list: D053918:Papillomavirus Vaccines